EUCTR2012-001112-29-DE进行中（未招募）1 期
A Prospective, randomized, single blind, multicenter Phase III study of organ perfusion with Custodiol-N solution compared with Custodiol solution in Heart transplantation
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Donor criteria:
- •- deceased donors should fulfil the criteria for organ donation (SCD)
- •Patient criteria
- •- recipients awaiting their first transplant
- •- recipients = 18 and - recipient’s signed informed consent
- •- waiting list
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 105
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Donor criteria:
- •- not applicable
- •Patient criteria
- •- recipients participating in another interventional study
- •- pregnant or lactating patients
- •- history/demonstration of HIV antibodies or AIDS
- •- multiorgan transplantation
- •- transMedics pump
- •- the explantation team is affiliated another clinic than transplantation team
研究者
相似试验
招募中
3 期
A prospective, randomized, single blind, multicentre phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in or-gan transplantation (kidney, liver and pancreas)2024-512444-29-00Dr. Franz Koehler Chemie GmbH362
进行中（未招募）
1 期
A Prospective, randomized, single blind, multicenter Phase III study of organ perfusion with Custodiol-N solution compared with Custodiol solution in Heart transplantatioEUCTR2012-001112-29-ATFa. Dr. Franz Köhler Chemie GmbH
进行中（未招募）
不适用
A Prospective, Randomized, Single Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerability of CDB-2914 with Levonorgestrel as Emergency Contraception Within 120 Hours Unprotected Intercourse ” (Phase III). - CDB-2914 vs LNG for ECEmergency contraceptionEUCTR2006-003387-55-IEaboratoire HRA Pharma2,044
招募中
3 期
A study to determine the effectiveness of BP16 (Denosumab)for treatment of Osteoporosis.CTRI/2023/11/059935CuraTeQ Biologics Private Ltd.
招募中
3 期
A study to evaluate the effect of BP11 (Omalizumab)for treatment of moderate to severe asthma.CTRI/2023/10/059224CuraTeQ Biologics Private Limited